It's True: Biosimilars Save Money for Medicare
MedPage Today,
Public Health & Policy > Health Policy Modest declines seen in Part B spending; but what does that mean for the private market?
Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
Overview of attention for article published in JAMA Health Forum, September 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (77th percentile)
Readers on
- mendeley
- 4 Mendeley